Home » Stocks » MNKD

MannKind Corporation (MNKD)

Stock Price: $3.21 USD 0.07 (2.23%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $3.26 +0.05 (1.56%) Jan 19, 7:59 PM
Market Cap 803.49M
Revenue (ttm) 62.69M
Net Income (ttm) -45.09M
Shares Out 229.67M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $3.21
Previous Close $3.14
Change ($) 0.07
Change (%) 2.23%
Day's Open 3.18
Day's Range 3.12 - 3.28
Day's Volume 3,454,593
52-Week Range 0.84 - 4.04

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 week ago

MannKind Corporation (MNKD) CEO Michael Castagna Presents at H.C. Wainwright Bioconnect 2021 Brokers Conference (Transcript)

GlobeNewsWire - 2 weeks ago

WESTLAKE VILLAGE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for ...

Zacks Investment Research - 3 weeks ago

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

WESTLAKE VILLAGE, Calif. and NEW PROVIDENCE, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and Vertice Pharma today announced that they have entered into a co-pro...

GlobeNewsWire - 1 month ago

Kent Kresa, former Chairman, will continue to serve as a Director Kent Kresa, former Chairman, will continue to serve as a Director

GlobeNewsWire - 1 month ago

Lead investigational product (inhaled clofazimine) designated by the FDA as an orphan drug and qualified infectious disease product Lead investigational product (inhaled clofazimine) designate...

GlobeNewsWire - 2 months ago

WESTLAKE VILLAGE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and coll...

PRNewsWire - 2 months ago

NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...

Seeking Alpha - 2 months ago

MannKind Corporation (MNKD) CEO Michael Castagna on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

MannKind (MNKD) delivered earnings and revenue surprises of -25.00% and -2.48%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

Conference Call to Begin Today at 5:00 PM ET

Seeking Alpha - 2 months ago

MannKind Corporation is a biopharma company focused on developing and commercializing inhaled therapeutics for endocrinology and lung diseases. Mannkind has one FDA-approved inhalable insulin ...

GlobeNewsWire - 2 months ago

WESTLAKE VILLAGE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference c...

Zacks Investment Research - 2 months ago

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 3 months ago

MannKind Corporation (MNKD) CEO Michael Castagna Presents at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Transcript)

Seeking Alpha - 4 months ago

MannKind Corporation (MNKD) CEO Michael Castagna Presents at Cantor 2020 Global Virtual Healthcare Conference (Transcript)

Seeking Alpha - 4 months ago

MannKind Corporation's (MNKD) CEO Michael Castagna at H.C. Wainwright 22nd Annual Global Investment Conference (Transcript)

Seeking Alpha - 4 months ago

MannKind Corporation's (MNKD) CEO Michael Castagna at H.C. Wainwright 2second Annual Global Investment Conference (Transcript)

GlobeNewsWire - 4 months ago

WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products f...

GlobeNewsWire - 4 months ago

WESTLAKE VILLAGE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman, MD, has joined the company as Vice President, Medical Af...

Zacks Investment Research - 4 months ago

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

WESTLAKE VILLAGE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products fo...

Seeking Alpha - 5 months ago

MannKind Corporation's (MNKD) CEO Michael Castagna on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

MannKind (MNKD) delivered earnings and revenue surprises of 0.00% and -0.52%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

Conference Call to Begin Today at 5:00 PM ET Conference Call to Begin Today at 5:00 PM ET

GlobeNewsWire - 5 months ago

WESTLAKE VILLAGE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conferenc...

Zacks Investment Research - 5 months ago

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Forbes - 6 months ago

Today has brought good news. Consumer confidence is better than expected and unemployment has decreased.

Other stocks mentioned: BCRX, FLNT, GRUB, LQDA
Forbes - 6 months ago

We will have to wait to see if the wind is truly changing to the bears, or if the bulls can come back throughout the day – either way, our deep learning algorithms paired with Artificial Intel...

Other stocks mentioned: FCEL, IDN, TTPH
Seeking Alpha - 6 months ago

MannKind Corporation (MNKD) CEO Michael Castagna Presents at Lytham Partners Virtual Investor Growth Conference (Transcript)

InvestorPlace - 6 months ago

Before you consider going all in on MNKD stock, consider that the company is itself going all in on one product, and that comes with risks. The post MannKind Is Crushing It, but Beware or You’...

Zacks Investment Research - 6 months ago

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zacks Investment Research - 7 months ago

Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.

GlobeNewsWire - 7 months ago

WESTLAKE VILLAGE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the Jun...

The Motley Fool - 7 months ago

Momentum is still in swing from the biotech's recent presentations.

The Motley Fool - 7 months ago

Investors liked the biotech's presentations at a major diabetes conference.

GlobeNewsWire - 7 months ago

WESTLAKE VILLAGE, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder wa...

GlobeNewsWire - 7 months ago

WESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder wi...

Forbes - 7 months ago

If there’s one thing that's been made more clear, it’s that the stock market and economy are not reflections of each other. An overbought stock market will eventually turn to the downside, and...

Other stocks mentioned: AGEN, BLNK, GRTS, OCGN
Forbes - 7 months ago

As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks t...

Other stocks mentioned: BBI, DGLY, EYPT, HTBX
Seeking Alpha - 8 months ago

MannKind Corporation's (MNKD) CEO Michael Castagna on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

MannKind (MNKD) delivered earnings and revenue surprises of 50.00% and 7.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

WESTLAKE VILLAGE, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective ...

The Motley Fool - 10 months ago

An overall market rebound and some company-specific news are lighting a fire beneath these stocks.

Other stocks mentioned: CODX, INO, NVAX
Seeking Alpha - 10 months ago

MannKind Corporation (MNKD) CEO Michael Castagna on Q4 2019 Results - Earnings Call Transcript

The Motley Fool - 10 months ago

The biotech met or exceeded Wall Street expectations in Q4. But its top and bottom lines are headed in the wrong direction.

Forbes - 1 year ago

Each year, MoneyShow asks the nation’s leading financial newsletter advisors for their favorite stocks for the coming year. Here are seven favorites from the pharmaceutical and biotechnology s...

Other stocks mentioned: ABBV, AMGN, AVXL, BMY, PFE, VRTX
24/7 Wall Street - 1 year ago

The short interest data are out for the most recent settlement date, December 13. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big p...

Other stocks mentioned: ALXN, AMGN, BIIB, GILD
GlobeNewsWire - 1 year ago

Publication in DIABETICMedicine Now Available Online Publication in DIABETICMedicine Now Available Online

About MNKD

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKi... [Read more...]

Industry
Biotechnology
IPO Date
Jul 28, 2004
CEO
Michael Castagna
Employees
232
Stock Exchange
NASDAQ
Ticker Symbol
MNKD
Full Company Profile

Financial Performance

In 2019, MNKD's revenue was $63.04 million, an increase of 126.28% compared to the previous year's $27.86 million. Losses were -$51.90 million, -40.32% less than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for MNKD stock is "Strong Buy." The 12-month stock price forecast is 3.30, which is an increase of 2.80% from the latest price.

Price Target
$3.30
(2.80% upside)
Analyst Consensus: Strong Buy